Wall Street analyst estimates for IN8bio, Inc. (INAB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.31 | ||
| 2026-08-06 | $-0.25 | $-0.34 | +27.3% |
| 2026-05-07 | $-0.26 | $-0.59 | +55.9% |
| 2026-03-12 | $-0.26 | $-0.18 | -44.4% |
| 2025-11-06 | $-0.85 | $-1.20 | +29.2% |
| 2025-08-07 | $-1.24 | $-1.50 | +17.3% |
| 2025-05-07 | $-2.10 | $-1.80 | -16.7% |
| 2025-03-13 | $-1.20 | $-0.07 | -1614.3% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $96000 | $96000 | 0 | 0 | 0 | $2.5M | 0 | $2.5M |
| Gross Profit | -$96000 | -$96000 | 0 | 0 | 0 | -$2.5M | 0 | -$2.5M |
| Research & Development | $581000 | $2.4M | $5.4M | $7.3M | $14.1M | $16.8M | $17.0M | $10.2M |
| Selling, General & Admin | $1.4M | $2.7M | $3.2M | $7.3M | $14.5M | $13.5M | $12.6M | $9.7M |
| Operating Expenses | $2.0M | $5.1M | $8.6M | $14.7M | $28.5M | $27.8M | $30.4M | $17.4M |
| Operating Income | -$2.0M | -$5.1M | -$8.6M | -$14.7M | -$28.5M | -$30.3M | -$30.4M | -$19.9M |
| EBITDA | -$2.0M | -$5.0M | -$8.5M | -$13.9M | -$27.4M | -$27.5M | -$26.9M | -$16.9M |
| Interest Expense | $14000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$2.1M | -$5.1M | -$8.6M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.1M | -$5.1M | -$8.6M | -$14.7M | -$28.5M | -$30.0M | -$30.4M | -$19.4M |
| EPS | $-3.89 | $-9.16 | $-16.03 | $-23.41 | $-40.81 | $-30.14 | $-17.05 | $-4.44 |
| EPS (Diluted) | $-3.89 | $-9.16 | $-16.03 | $-23.41 | $-40.81 | $-30.14 | $-17.05 | $-4.44 |
| Shares Outstanding (Diluted) | $645151 | $645151 | $645151 | $626041 | $698931 | $995497 | $1.8M | $4.4M |
Price
| Price | $1.01 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · APVO · BCDA · GLTO · HCWB · KPRX
Explore sector: Healthcare · Biotechnology
More sections of INAB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks